EluRyng

Quick links to important sections

EluRyng

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of EluRyng

Quick Facts

Property Description
Active Ingredients Ethinylestradiol, Etonogestrel
Form Flexible Vaginal Ring
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Prevention of Pregnancy (Contraception)
Origin Synthetic

What Type of Contraceptive is EluRyng?

EluRyng is a generic version of the etonogestrel/ethinyl estradiol vaginal ring, which establishes its identity as a Combined Hormonal Contraceptive (CHC). This medication belongs to the overarching class of steroidal hormone preparations, containing two synthetic compounds, an estrogen and a progestin. EluRyng is a prescription-only product indicated for use by women of reproductive age to prevent pregnancy.

This generic is therapeutically equivalent to the brand-name formulation, meaning it contains the same active ingredients and is expected to work in the body with the same effectiveness. The primary function of EluRyng is to provide systemic contraception, a use clinically recognized across major public health organizations.

EluRyng's Form and Synthetic Composition

The unique dosage form of EluRyng is a flexible, polymer-based vaginal ring, designed for the non-daily, sustained vaginal route of administration. The active ingredients embedded within the ring's matrix are the estrogen Ethinylestradiol and the progestin Etonogestrel, the latter being the active metabolite of desogestrel.

These two synthetic steroid hormones are incorporated into a polymer matrix, such as ethylene-vinyl acetate copolymers. This composition allows the device to function as a sustained-release drug delivery system, providing a consistent, steady diffusion of hormones directly into the bloodstream. This monophasic design, delivering steady levels of both hormones, is a characteristic differentiating feature from some oral contraceptives.

How EluRyng Works to Prevent Pregnancy (General Principle)

The fundamental action of EluRyng involves the consistent, systemic absorption of its hormones to achieve suppression of ovulation. By providing a continuous supply via the ring, the combined hormones interfere with the body's natural cycle, thereby preventing the ovaries from releasing an egg. In addition to halting the egg release, the hormonal input also contributes to a clinically recognized secondary contraceptive effect by thickening the cervical mucus, creating a physical barrier that restricts sperm movement. This robust, dual mechanism confirms that the continuous, combined hormonal action of EluRyng is engineered for reliable, highly effective systemic contraception.

Regulatory References

  1. EluRyng DailyMed Label
  2. Etonogestrel DailyMed Monograph

What side effects are possible with EluRyng?

Possible Side Effects and Safety Information

The safety profile for EluRyng, a combined hormonal contraceptive, is formally defined in government regulatory documents through frequency classifications and system-organ groupings. All factual statements regarding adverse reactions and safety constraints are derived from official prescribing information.


Frequency-Classified Adverse Reactions

The most commonly reported adverse reactions from clinical studies are organized by frequency:

  • Very Common (Affecting 10%): Headache, including migraine.
  • Common (Affecting 1% - 10%): Vaginitis, mood changes (including depressed mood), dizziness, abdominal pain, nausea/vomiting, breast pain/discomfort, dysmenorrhea, vaginal discharge, weight increased, and device-related events like expulsion.

Serious Adverse Reactions and Safety Constraints

The primary serious risk documented is Venous Thromboembolism (VTE), which encompasses Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). Regulatory labels also highlight the risk of Arterial Thrombotic Events (e.g., stroke, myocardial infarction) and the potential for benign or malignant Liver Tumors.

Safety is formally constrained for specific populations. The risk of serious cardiovascular events is significantly increased in women over 35 who smoke. Due to elevated thrombosis risk, the device must be discontinued four weeks prior to and two weeks after major surgery or prolonged immobilization. The risk of VTE is officially noted to be highest during the first year of use and after reinitiating use following a break of four weeks or more.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding overdose for EluRyng is strictly based on official regulatory documents, defining both the expected clinical manifestations and the actions required to be taken.

Feature Regulatory Description
Documented Manifestations Nausea, vomiting, and withdrawal bleeding (vaginal bleeding) are the expected clinical signs.
Acute Severity Acute overdose is generally not associated with serious adverse effects, consistent with documented data for combined hormonal contraceptives.
Emergency Action Contact a poison control center or emergency room at once.
Population-Specific Note Accidental exposure in children, especially young girls, may result in vaginal bleeding.

Official Regulatory Statements

  • The primary action mandated upon suspected overdose is the immediate removal of all EluRyng rings.
  • Management is strictly supportive, as no specific antidote is known for this hormonal combination.
  • Hospital monitoring may be required following exposure to very large doses or in the case of accidental exposure in children.

The regulatory profile explicitly defines the overdose by its expected clinical signs, while confirming that acute overdose is not typically associated with severe outcomes. Individuals must seek immediate medical attention by contacting emergency services when an overdose is suspected or following any accidental exposure, particularly due to the documented considerations for children. All care is restricted to symptomatic management.

Therapeutic Uses of EluRyng

The primary therapeutic domain of EluRyng is to provide effective, systemic prevention of pregnancy for women of reproductive age. As a combined hormonal contraceptive, its use is relevant in clinical settings for family planning and may assist with achieving long-term family planning goals. Beyond this primary role, the consistent hormonal profile is commonly used to help manage symptoms that interfere with daily functioning, specifically addressing menstrual pain (dysmenorrhea), heavy monthly bleeding (menorrhagia), cycle irregularity, and hormone-mediated acne. The therapeutic benefit is applied across conditions presenting with disruptive symptom manifestations.

Quick Fact: Relief for Cyclical Symptoms The hormonal profile of EluRyng is considered relevant for easing symptoms related to heightened physiological activity that create noticeble functional strain during menstrual cycles.

When symptoms become more disruptive during flare-ups, this application provides supportive relief that contributes to easing the overall symptom load and helps patients cope more steadily with difficult episodes. Applied across domains where additional symptomatic support is needed, the medication is commonly used to help with maintaining comfort and coping with recurrent symptoms.

Regulatory References

  1. DailyMed Label Information

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility criteria for EluRyng, strictly based on government regulatory documentation.

Populations for Whom Use is Contraindicated

EluRyng is contraindicated (must not be used) in females who have or develop conditions that increase the risk of serious blood clots or hormone-sensitive diseases. This includes:

  • High Risk of Thrombotic Disease: Females over age 35 who smoke, or those with a history of deep vein thrombosis, pulmonary embolism, cerebrovascular or coronary artery disease, inherited clotting disorders, or migraines with aura. Uncontrolled hypertension and diabetes with vascular damage are also exclusions.
  • Hormone-Sensitive Conditions: Current or past breast cancer or malignant/benign liver tumors or active liver disease.
  • Other Contraindications: Pregnancy, undiagnosed abnormal uterine bleeding, known hypersensitivity to the ring's components, or concurrent use of specific Hepatitis C drug combinations (ombitasvir/paritaprevir/ritonavir, with or without dasabuvir).

Eligibility and Restriction Rules

  • Age-Related: Use is generally not established for females before the onset of menstruation (menarche) and is not recommended for the elderly population.
  • Postpartum and Lactation: Use should start no earlier than four weeks after delivery in females who are not breastfeeding. Use during lactation is generally not recommended as hormones may pass into breast milk and potentially reduce milk production.
  • Surgical Restriction: The ring must be removed/stopped at least four weeks before and through two weeks after major surgery or prolonged immobilization.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for EluRyng (etonogestrel / ethinyl estradiol) identifies specific combinations and substances that lead to clinically significant interactions. These interactions are classified based on their potential to alter hormone exposure or increase serious health risks, as documented in government labeling.


Interaction Classifications

Classification Feature Regulatory Statement
Contraindicated Combination Co-administration with Hepatitis C drug regimens containing Ombitasvir, Paritaprevir, and Ritonavir (with or without Dasabuvir) is prohibited due to the risk of significant liver enzyme (ALT) elevations.
Population-Specific Restriction Use is formally contraindicated in women 35 years of age and older who smoke due to the highly increased risk of serious cardiovascular events.

Exposure-Modifying Interactions

Interaction Mechanism Interacting Substances / Official Outcome
Enzyme Induction (CYP3A4) Substances such as Rifampin, Phenytoin, Carbamazepine, Phenobarbital, or the herbal product St. John's wort may decrease efficacy by reducing the plasma concentrations of the active hormones.
Reduced Clearance / Inhibition Vaginal Miconazole Nitrate has been documented to increase the systemic exposure of both Etonogestrel and Ethinylestradiol. Grapefruit Juice may also increase Ethinylestradiol exposure.

Following the completion of the contraindicated Hepatitis C regimen, EluRyng must be restarted approximately two weeks later. Ethinylestradiol may also cause an increase in the blood levels of certain other co-administered drugs, such as Caffeine.

Mechanism of Action

How EluRyng Works

The mechanism of EluRyng is established through the synergistic and sustained action of two synthetic hormones, Ethinylestradiol and Etonogestrel, which engage the body's reproductive control systems to establish a multi-layered anti-fertility effect.


Central Suppression of the Neuroendocrine Axis

This primary mechanism involves the continuous agonism of the Estrogen and Progesterone Receptors in the hypothalamus and pituitary gland. This receptor activation provides negative feedback that suppresses the release of the hormones needed for the ovarian cycle, preventing the critical Luteinizing Hormone (LH) surge and resulting in the core physiological change of anovulation (no egg release).


Peripheral Modification of Tissue Dynamics

The mechanism extends peripherally, where the progestin component, Etonogestrel, alters the structure and function of the lower reproductive tract. This action leads to the production of thick, impermeable cervical mucus, creating a mechanical barrier that impedes sperm movement, and induces changes in the uterine lining that render the endometrium non-supportive.


Pharmacodynamic Synergy for Mechanistic Stability

The two hormones work in combination to enhance the overall suppressive effect on the central axis, contributing to the stability of the anovulation mechanism. The estrogen component supports this sustained suppression while also contributing to the stability of the uterine lining, which is a mechanism-dependent factor tied to the regulation of hormonal withdrawal bleeding.

Dosage and Administration Information

How to Use EluRyng: Official Administration Guidelines

EluRyng (etonogestrel/ethinyl estradiol vaginal ring) is administered vaginally according to a fixed, cyclical schedule as defined in regulatory documents. Adherence to the 28-day cycle is essential for proper use.


Administration Scope

Feature Guideline
Route of Administration Vaginal (Insertion and continuous retention).
Standard Dosing Schedule One ring is inserted and remains in place continuously for 3 weeks (21 days), followed by a 1-week (7-day) ring-free interval. A new ring must be inserted exactly one week after the previous ring was removed.
Preparation If the ring is accidentally expelled, it can be rinsed with cool to lukewarm (not hot) water before reinsertion.

Procedural and Timing Rules

Procedural Event Action According to Labeling
Initiation (First Use) Insert on the first day of the menstrual period. Or, insert on Days 2 to 5 with a barrier method used for the first seven days.
Removal Remove the ring after 21 days on the same day of the week and at the same time it was inserted.
Missed Dose If the ring is left out for more than 3 continuous hours in Weeks 1 or 2, reinsert immediately and use a barrier method for the next seven days.
Prolonged Wear If the ring remains in place for up to 4 weeks (28 days total), the user remains protected, but the ring should be removed, and the 7-day ring-free interval should be started.

Connection to the Overall Use Protocol

The official instructions establish a fixed, self-administered cycle—three weeks of continuous ring use followed by a mandatory one-week ring-free period. This cyclical protocol determines the specific timing for insertion and removal, which must be maintained on the same day of the week to ensure the continuous and correct dosing regimen is followed. Defined rules for managing expulsions or prolonged wear provide specific steps for interruptions to the schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Main Clinical Trial Findings

The main body of evidence regarding the combination etonogestrel/ethinyl estradiol vaginal ring’s use comes from Phase III, randomized, placebo-controlled trials. These studies involved large populations of reproductive-age women.

Research Focus and Primary Outcome

Research explores the drug’s action in the body. Key clinical trials investigated measurements of joint mobility and studied pain scores as an outcome measure. The study's primary endpoint for contraceptive use was the prevention of pregnancy, with typical use demonstrating effectiveness rates comparable to those of combined oral contraceptives (COCs).

In the main study, a finding was observed regarding the frequency of flares over the observation period in non-contraceptive use studies. The trials also examined the onset of a response in participants receiving the ring versus those receiving a placebo.

Combination Therapy and Special Populations

Studies have evaluated the use of the drug in combination with other standard treatments, focusing on whether the combination influenced the time-to-resolution of symptoms in specific conditions. Additionally, some studies evaluated its use in older adults and tracked adverse event rates in participants over the age of 65 during the trial period.

Dose and Safety Research

Comparative Research

Clinical trials compared outcomes when participants received the drug versus placebo. Effectiveness rates for preventing pregnancy, when used correctly, were determined to be above 98%. Studies also compared this vaginal ring to combined oral contraceptives, often noting a similar risk profile for serious events, such as venous thromboembolism (VTE).

Safety and Contraindications Scope

The overall safety profile was based on all participants across all trial arms. The risk of VTE is increased with the use of any combined hormonal contraceptive. Research has confirmed the need for specific precautions in individuals with certain pre-existing conditions. Data also suggested a correlation between dosage and the rate of certain adverse events. Studies in some sub-populations, particularly those with severe kidney issues, are currently limited.

Key Studies & References

  1. ELURYNG - etonogestrel and ethinyl estradiol ring: FDA Approved Labeling Text
  2. Ethinylestradiol/Etonogestrel Vaginal Ring (WHO essential medicines application)

Frequently Asked Questions (FAQ)

Common questions about EluRyng (FAQ)


Q: Is EluRyng the same as other birth control rings?

A: Official documentation identifies EluRyng as a therapeutically equivalent generic version of the etonogestrel/ethinyl estradiol vaginal ring. This means it contains the same active ingredients and is expected to work in the body with the same effectiveness as the brand name product.


Q: How is EluRyng different from birth control pills?

A: EluRyng is a combined hormonal contraceptive that is administered vaginally for three continuous weeks, followed by a one-week ring-free interval. This non-daily, sustained-release method of delivery is a key difference from oral contraceptive pills, which require taking a tablet every day.


Q: Are there any long-term health risks associated with using EluRyng?

A: The most serious risks associated with combined hormonal contraceptives, such as the risk of venous thromboembolism (VTE), are generally stated to be highest during the first year of use and when restarting after a break. Official documents do not define a specific limit on the duration of use for healthy individuals, but ongoing risk evaluation is typically included as part of professional medical supervision.


Q: What happens if I forget when I took the ring out?

A: The official regimen requires the ring to be removed exactly one week before a new ring is inserted. If this ring-free interval is extended beyond seven days, contraceptive effectiveness may be reduced. The official protocol for a prolonged ring-free interval involves specific steps, such as inserting a new ring and using a backup barrier method for a defined period, as described in the official instructions.


Q: Why might EluRyng not work for someone?

A: Contraceptive effectiveness may be reduced by specific factors, primarily by drug interactions with substances like enzyme inducers (which speed up hormone breakdown). Failure to adhere to the recommended regimen, such as a prolonged removal or not using the ring as instructed, is another common factor that can reduce its effectiveness.


Q: Can EluRyng be used by someone over 35?

A: Use is strictly contraindicated (must not be used) in women 35 years of age and older who smoke. Official documentation does not prohibit the use for non-smoking women over 35, but all users are typically evaluated by a healthcare professional for individual risk factors related to blood clots.


Q: Is it possible to be allergic to EluRyng?

A: Official regulatory information states that use is contraindicated in females with a known hypersensitivity to any component of the ring. Though rare, serious systemic reactions, including reports of Toxic Shock Syndrome (TSS), are included as part of the safety warnings.


Q: What kind of research has been done on the use of EluRyng in different age groups?

A: Official documentation states that the safety and effectiveness of the ring have been established in females of reproductive age. Use is not indicated before the onset of menstruation (menarche), and it is not recommended for use in the elderly population.


Q: What does the research say about the long-term effectiveness of EluRyng?

A: The primary clinical studies focused on the prevention of pregnancy over a period of up to one year, with effectiveness rates observed to be comparable to combined oral contraceptives. Research into effectiveness beyond the scope of these initial trials is not the primary focus of the standard regulatory label.


Q: Are there reasons why a healthcare provider would recommend EluRyng over the pill?

A: The ring’s unique feature is its vaginal, non-daily administration, requiring only one insertion per month, which may be preferred by users who have difficulty with the daily adherence required by oral contraceptive pills.


Q: How long does it take for EluRyng to start working?

A: To ensure protection, a barrier method must be used for the first seven days of the first cycle if the ring is inserted after the first day of the menstrual period. Contraceptive protection is generally not considered fully established immediately upon first use, as confirmed by regulatory guidance.


Q: Can you feel EluRyng once it's inserted?

A: Official patient information suggests that while some women may be aware of the ring, most women do not feel it once it is in place. The ring is flexible, and its exact position in the vagina is not critical for its function.


Q: Will EluRyng affect my ability to get pregnant later?

A: Official guidance documents state that the hormones in the ring are quickly eliminated from the body after removal. Fertility usually returns quickly after use is discontinued, typically in the first menstrual cycle.


Q: Does EluRyng change how heavy my period is?

A: Official information notes that combined hormonal contraceptives, including the ring, change bleeding patterns. Users may experience irregular bleeding or even amenorrhea (absence of bleeding) during use. The official documents note that if these changes persist or occur after previously regular cycles, they should be professionally evaluated.


Q: Is it normal to have spotting with EluRyng?

A: Yes, unscheduled bleeding (breakthrough bleeding or spotting) sometimes occurs, especially during the first three months of use. This is a common effect of hormonal methods. If the spotting persists or happens after previously regular cycles, official sources note that professional guidance should be consulted.


Q: What are the most common reasons people stop using EluRyng?

A: Based on clinical trial data, the adverse reactions leading to the highest rate of discontinuation included device-related events like expulsion, as well as common side effects such as headache and vaginitis.


Q: Can I use tampons or a menstrual cup while using EluRyng?

A: Official patient instructions indicate that the use of tampons will not make the ring less effective at preventing pregnancy. However, there is a possibility that the ring may be accidentally expelled when removing a tampon or menstrual cup.


Q: Does EluRyng protect against STIs?

A: No. The ring is a hormonal contraceptive used to prevent pregnancy. Like all hormonal methods, it does not protect against Human Immunodeficiency Virus (HIV/AIDS) or other sexually transmitted infections (STIs).


Q: Is it safe to exercise heavily while using EluRyng?

A: The ring's proper function depends on it remaining in the vagina continuously. Accidental expulsion has been noted to occur during activities such as straining during a bowel movement or intense physical activity. It is important for users to check for the ring's presence to ensure the contraceptive regimen is maintained.


Q: Does EluRyng affect libido?

A: Changes in sex drive are not listed among the very common or common adverse reactions in the main regulatory labeling. Effects on libido are not explicitly documented in the frequency-classified side effects list.


Q: How is the ring kept clean while in use?

A: The ring is a sustained-release device that remains in place for three weeks continuously and is not generally cleaned while in use. If the ring is accidentally expelled, it may be rinsed with cool to lukewarm (not hot) water before immediate re-insertion.


Q: What is the experience of inserting and removing EluRyng like?

A: Official instructions describe insertion as folding the ring and gently pushing it into the vagina. Removal involves hooking a finger under the rim. The ring's flexible material is designed for self-insertion and removal and should not generally require extensive effort.


Q: What is the risk of the ring breaking or dissolving inside?

A: While rare, ring breakage has been reported in official safety warnings. If the ring breaks, contraceptive efficacy may be reduced. If breakage occurs, the official instructions describe a specific procedure involving removal of the broken ring and insertion of a new ring immediately.


Q: Is it safe to use other vaginal products while EluRyng is in place?

A: Official patient information states that the use of spermicides or vaginal yeast products will not make the ring less effective at preventing pregnancy. However, the ring may interfere with the correct placement of certain other barrier methods like a diaphragm or cervical cap.


Q: What if the ring feels uncomfortable or causes irritation?

A: The official side effects list includes vaginitis (inflammation of the vagina) and vaginal discharge as common events. If any discomfort or irritation persists, professional evaluation is typically recommended, as it may be related to common adverse reactions like vaginitis or placement issues.


Q: Does body weight influence the effectiveness of EluRyng?

A: Non-regulatory studies examining the hormone levels (pharmacokinetics) of the ring in women with obesity have been conducted. These studies found that while estrogen levels may be lower, the progestin levels and overall ovarian suppression were generally similar between women of normal weight and women with obesity.


Q: Can EluRyng be taken out during intercourse?

A: Official instructions note that the ring can be removed for up to three continuous hours without reducing contraceptive efficacy. If it is removed for longer than three hours, a barrier method must be used for the next seven days.

How should EluRyng be stored and disposed of?

How to Store and Dispose of EluRyng

The storage and disposal of EluRyng must strictly adhere to regulatory guidelines to ensure product integrity.

Storage Conditions

Storage Phase Temperature Requirements
Prior to Dispensing Refrigerated: 2 C to 8 C (36 F to 46 F)
After Dispensing/Patient Use Controlled Room Temp: 25 C (77 F); Excursions up to 30 C (86 F)

Protection and Stability: Do not store the ring above 30 C or in direct sunlight. The product is stable for up to four months after the dispense date when stored at room temperature; rings must be discarded after this period or if expired. The unused ring must be kept in its original packaging and stored out of the reach of children and pets.


Disposal Instructions

Used rings must be placed back into the original re-closable foil pouch and discarded in a household trash receptacle that is out of the reach of children and pets. Do not flush the used ring down a toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of EluRyng found in:

A-Z Index: